Dimensional Fund Advisors LP Acquires 1,074,274 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Dimensional Fund Advisors LP boosted its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 6.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,900,987 shares of the company's stock after purchasing an additional 1,074,274 shares during the period. Dimensional Fund Advisors LP owned about 3.62% of Elanco Animal Health worth $216,774,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Elanco Animal Health in the third quarter worth approximately $35,000. Jones Financial Companies Lllp boosted its stake in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after acquiring an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. boosted its stake in shares of Elanco Animal Health by 221.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock worth $60,000 after acquiring an additional 3,411 shares during the last quarter. MRP Capital Investments LLC bought a new stake in shares of Elanco Animal Health during the 4th quarter valued at $61,000. Finally, Blue Trust Inc. increased its stake in shares of Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after purchasing an additional 1,894 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction dated Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now owns 111,459 shares of the company's stock, valued at $1,136,881.80. The trade was a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.89% of the stock is currently owned by company insiders.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock traded up $0.03 on Monday, hitting $9.49. 637,682 shares of the company traded hands, compared to its average volume of 4,916,370. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The business has a 50-day simple moving average of $10.03 and a 200 day simple moving average of $11.62. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.80. The stock has a market capitalization of $4.71 billion, a P/E ratio of 23.69, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.08 EPS. Research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ELAN has been the topic of several analyst reports. Stifel Nicolaus lowered their target price on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Morgan Stanley lowered their price objective on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. UBS Group reduced their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Barclays lowered their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Finally, Piper Sandler decreased their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $14.67.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.